Trial · NCT01263925
Outcomes14
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Ratio of Pain-free Walking Distance After Period 2 in Comparison With the Findings at Baseline | From Baseline to the end of 4 weeks of Interval Treatment (Period 2) | Full Analysis Set (FAS). | meter/meter | MEAN |
| PRIMARY | Ratio of Pain-free Walking Distance After Period 3 in Comparison With the Findings at Baseline | From Baseline to the end of 6-months Follow-up (Period 3) | Full Analysis Set (FAS). | meter/meter | MEAN |
| PRIMARY | Ratio of Pain-free Walking Distance After Period 1 in Comparison With the Findings at Baseline | From Baseline to the end of 4 weeks of Daily Treatment (Period 1) | Full Analysis Set (FAS). | meter/meter | MEAN |
| SECONDARY | Ratio of Pain-free Walking Distance After Period 2 in Comparison With the Findings After Period 1 | From the end of 4 weeks of Daily Treatment (Period 1) to the end of 4 weeks of Interval Treatment (Period 2) | Full Analysis Set (FAS). | meter/meter | MEAN |
| SECONDARY | Ratio of Pain-free Walking Distance After Period 3 in Comparison With the Findings After Period 1 | From the end of 4 weeks of Daily Treatment (Period 1) to the end of 6-months Follow-up (Period 3) | Full Analysis Set (FAS). | meter/meter | MEAN |
| SECONDARY | Ratio of Pain-free Walking Distance After Period 3 in Comparison With the Findings After Period 2 | From the end of 4 weeks of Interval Treatment (Period 2) to the end of 6-months Follow-up (Period 3) | Full Analysis Set (FAS). | meter/meter | MEAN |
| SECONDARY | Ratio of Maximum Walking Distance After Period 1 in Comparison With the Findings at Baseline | From Baseline to the end of 4 weeks of Daily Treatment (Period 1) | Full Analysis Set (FAS). | meter/meter | MEAN |
| SECONDARY | Ratio of Maximum Walking Distance After Period 2 in Comparison With the Findings at Baseline | From Baseline to the end of 4 weeks of Interval Treatment (Period 2) | Full Analysis Set (FAS). | meter/meter | MEAN |
| SECONDARY | Ratio of Maximum Walking Distance After Period 2 in Comparison With the Findings After Period 1 | From the end of 4 weeks of Daily Treatment (Period 1) to the end of 4 weeks of Interval Treatment (Period 2) | Full Analysis Set (FAS). | meter/meter | MEAN |
| SECONDARY | Ratio of Maximum Walking Distance After Period 3 in Comparison With the Findings at Baseline | From Baseline to the end of 6-months Follow-up (Period 3) | Full Analysis Set (FAS). | meter/meter | MEAN |
| SECONDARY | Ratio of Maximum Walking Distance After Period 3 in Comparison With the Findings After Period 1 | From the end of 4 weeks of Daily Treatment (Period 1) to the end of 6-months Follow-up (Period 3) | Full Analysis Set (FAS). | meter/meter | MEAN |
| SECONDARY | Ratio of Maximum Walking Distance After Period 3 in Comparison With the Findings After Period 2 | From the end of 4 weeks of Interval Treatment (Period 2) to the end of 6-months Follow-up (Period 3) | Full Analysis Set (FAS). | meter/meter | MEAN |
| SECONDARY | Changes in Quality of Life (as Measured With the PAVK 86 Questionnaire) From Baseline to the End of Period 1 | From Baseline to the end of 4 weeks of Daily Treatment (Period 1) | Full Analysis Set (FAS). For each subscale of the questionnaire, Mean and SD are presented for non-missing values. | units on a scale | MEAN |
| SECONDARY | Changes in Quality of Life (as Measured With the PAVK 86 Questionnaire) From Baseline to the End of Period 3 | From Baseline to the end of 6-months Follow-up (Period 3) | Full Analysis Set (FAS). For each subscale of the questionnaire, Mean and SD are presented for non-missing values. | units on a scale | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01263925/outcomes